Viewing Study NCT04076137



Ignite Creation Date: 2024-05-06 @ 1:38 PM
Last Modification Date: 2024-10-26 @ 1:17 PM
Study NCT ID: NCT04076137
Status: UNKNOWN
Last Update Posted: 2019-09-03
First Post: 2019-08-29

Brief Title: Targeted T-cell Therapy in Solid Tumors
Sponsor: Benhealth Biopharmaceutical Shenzhen Co Ltd
Organization: Benhealth Biopharmaceutical Shenzhen Co Ltd

Study Overview

Official Title: Clinical Study of Targeted T-cell Therapy in Solid Tumors
Status: UNKNOWN
Status Verified Date: 2019-08
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a single-center open single-arm controlled prospective clinical trial of patients with solid tumors treated with targeted activation of T cells through intravenous infusionThe purpose of this study was to evaluate the clinical efficacy and safety of targeted activated T cells in the treatment of solid tumors
Detailed Description: In China malignant tumors have become the leading cause of death for urban and rural residents with solid tumors accounting for 77 percentImmunotherapy is considered one of the most promising ways to fight cancerThis study is a single-center open single-arm controlled clinical trial after intravenous infusion of targeted T cells compare the changes of self-lesion The essence of this study is to collect immune cells to the surrounding of tumor cells so that immune cells can kill tumor cells at close rangeThe researchers plan to enroll 10 patients with solid tumors and follow them up to the end of the study after completing 9 courses of treatmentThe results of this study were statistically analyzed using RECIST11 records

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None